Compare VST & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VST | EW |
|---|---|---|
| Founded | 1882 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1B | 50.2B |
| IPO Year | 2016 | 1999 |
| Metric | VST | EW |
|---|---|---|
| Price | $147.64 | $79.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | ★ $234.09 | $96.37 |
| AVG Volume (30 Days) | 3.7M | ★ 5.2M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.87 | 0.66 |
| Revenue | ★ $17,738,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $30.97 | $13.39 |
| Revenue Next Year | $9.19 | $9.81 |
| P/E Ratio | ★ $71.23 | $125.47 |
| Revenue Growth | 2.98 | ★ 11.55 |
| 52 Week Low | $138.53 | $72.30 |
| 52 Week High | $219.82 | $87.89 |
| Indicator | VST | EW |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 42.71 |
| Support Level | $143.72 | $76.92 |
| Resistance Level | $169.32 | $83.19 |
| Average True Range (ATR) | 6.79 | 2.41 |
| MACD | -0.90 | -0.04 |
| Stochastic Oscillator | 1.55 | 4.43 |
Vistra Corp. is one of the largest power producers and retail energy providers in the USA. It owns 44 gigawatts of generation capacity, including natural gas (27 GW), nuclear (6.5 GW), coal (8.7 GW), and solar and battery storage (1.4 GW). The Cogentrix acquisition will add 5.5 GW of gas generation. Vistra's retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.